Sana Biotechnology Inc vs Global X Defense Tech ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Global X Defense Tech ETF trades at $61.96. Which is the better fit depends on your goals.
| SANA | SHLD | |
|---|---|---|
Market Cap | $1.03B | — |
Sector | Health | Sector/Thematic |
52-Week High | $5.92 | $78.02 |
52-Week Low | $2.68 | $58.20 |
Enterprise Value | $946.04M | — |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
SHLD (Global X Defense Tech ETF) trades at $62.72, down 0.41% on the day, with a bearish technical signal overall despite oversold RSI readings. The ETF offers diversified exposure to global defense technology firms, with institutional buying interest noted in recent filings. Key support sits at $62, while resistance is at $63-$64.
Outlook is supported by rising global defense spending and geopolitical shifts, but risks include high launch costs for space-related holdings and ETF expense comparisons. The technical setup suggests potential for a near-term rebound from oversold levels, though moving averages remain bearish.
Trailing returns across standard periods
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →